Related Experiment Videos
Cytokine modulation in sepsis and septic shock
Sergio Zanotti1, Aseem Kumar, Anand Kumar
1Section of Critical Care Medicine, Rush-Presbyterian-St. Luke's Medical Center, Room 214 Jones, 1635 west Congress Parkway, Chicago, Illinois 60612, USA. szanotti@rush.edu
Expert Opinion on Investigational Drugs
|August 2, 2002
Summary
Sepsis, a critical condition, involves complex cytokine responses. This review explores clinical trials targeting pro-inflammatory cytokines like TNF-alpha and IL-1beta to improve patient outcomes.
Area of Science:
- Critical care medicine
- Immunology
- Molecular biology
Background:
- Sepsis and septic shock are leading causes of intensive care unit mortality.
- Despite antibiotics, sepsis mortality remains high (30-50%).
- Sepsis involves a systemic response with pro- and anti-inflammatory cytokine phases.
Purpose of the Study:
- To review clinical trials evaluating strategies to block or attenuate TNF-alpha and IL-1beta activity.
- To survey experimental therapies involving IL-10, TGF-beta, G-CSF, and IFN-phi.
- To evaluate newer developments in sepsis treatment targeting cytokines like MIF and HMGB1.
Main Methods:
- Review of clinical trials on cytokine modulation in sepsis.
- Survey of experimental therapies for sepsis.
- Evaluation of emerging cytokine targets in sepsis.
Main Results:
- Multiple clinical studies have investigated modulating pro- and anti-inflammatory cytokines to improve sepsis outcomes.
- Various strategies targeting TNF-alpha and IL-1beta have been evaluated.
- Experimental therapies involving IL-10, TGF-beta, G-CSF, and IFN-phi are under investigation.
Conclusions:
- Modulating cytokine activity is a key area of research for improving sepsis outcomes.
- Targeting pro-inflammatory cytokines like TNF-alpha and IL-1beta shows therapeutic potential.
- Emerging cytokine targets offer new avenues for sepsis treatment.